Prognostic significance of G2/M arrest signaling pathway proteins in advanced non-small cell lung cancer patients
Authors:
Open Access
- 2 January 2015
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (3) , 1266-1272
Abstract
The aim of the present study was to retrospectively assess the correlation between the expression levels of proteins involved in G2/M arrest signaling pathways in non‑small cell lung cancer (NSCLC) tissue, as determined by immunohistochemical (IHC) methods, and the overall survival of patients with advanced stage NSCLC. IHC analysis of advanced NSCLC specimens was used to determine the expression levels of proteins involved in G2/M arrest signaling pathways, including ataxia telangiectasia mutated (ATM) kinase, ataxia telangiectasia and Rad3‑related (ATR) kinase, checkpoint kinase (Chk) 1, Chk2, cell division cycle 25C (Cdc25C), total cyclin‑dependent kinase 1 (Cdk1) and active Cdk1 signaling pathways, the latter of which refers to dephospho‑Cdk1 (Tyr15) and phospho‑Cdk1 (Thr161). Patients were enrolled continuously and followed up for ≥2 years. Univariate analysis demonstrated that the protein expression levels of dephospho‑Cdk1 (P=0.015) and phospho‑Cdk1 (P=0.012) exhibited prognostic significance, while the expression of the other proteins was not significantly associated with patient survival (ATM, P=0.843; ATR, P=0.245; Chk1, P=0.341; Chk2, P=0.559; Cdc25C, P=0.649; total Cdk1, P=0.093). Furthermore, the patients with tumors exhibiting low expression levels of active Cdk1 survived significantly longer than those with tumors exhibiting high active Cdk1 expression levels (P<0.05). In addition, Cox regression analysis demonstrated that the expression of active Cdk1 [odds ratio (OR), 0.624; 95% confidence ratio (CI), 0.400‑0.973; P=0.038] and the pathological tumor‑node‑metastasis stage (OR, 0.515; 95% CI, 0.297‑0.894; P=0.018) were significant independent prognostic factors for NSCLC. Therefore, the results of the present study indicated that active Cdk1 protein is an independent prognostic factor for advanced NSCLC and may validate Cdk1 as a therapeutic target for advanced NSCLC patients.Keywords
This publication has 33 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerNew England Journal of Medicine, 2013
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Middle Infrared Radiation Induces G2/M Cell Cycle Arrest in A549 Lung Cancer CellsPLOS ONE, 2013
- Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung CancerJournal of Thoracic Oncology, 2010
- Diallyl trisulfide selectively causes Bax‐ and Bak‐mediated apoptosis in human lung cancer cellsEnvironmental and Molecular Mutagenesis, 2008
- ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancerLung Cancer, 2008
- Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecinsMolecular Cancer Therapeutics, 2008
- A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutationsBritish Journal of Cancer, 2006
- Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1Proceedings of the National Academy of Sciences, 2006